Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 17/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415974 | 0.82 | ITK (0.62) | ITKKDRFGFR1 | |
| SCHEMBL6409013 | 0.73 | KDR (0.45) | KDRFGFR1CHEK1CDK4CCND1 | |
| SCHEMBL6409018 | 0.73 | KDR (0.45) | KDRFGFR1CHEK1CDK4CCND1 | |
| SCHEMBL6410583 | 0.72 | CLK2 (0.49) | ITK | |
| SCHEMBL12895653 | 0.71 | ABL1 (0.45) | KDR | |
| SCHEMBL6410524 | 0.70 | ITK (0.52) | ITKCHEK1 | |
| SCHEMBL4136943 | 0.67 | CA12 (0.49) | KDRCDK4CCNA2CCND1CDK2 | |
| SCHEMBL6408513 | 0.67 | MAPT (0.57) | KDRCCNA2CDK2 | |
| SCHEMBL34468781 | 0.66 | SMYD3 (0.55) | KDRCHEK1 | |
| SCHEMBL5638533 | 0.66 | ITK (0.81) | ITKKDRFGFR1CHEK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884123-B2 | 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-7884123-B2 | 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | TYMS, TYMP, CYP3A43 | ITK 961/4885KDR 2229/4885FGFR1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.